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Syzygium cumini (Myrtaceae) is a worldwide medicinal plant traditionally used in
herbal medicines due to its vaunted properties against cardiometabolic disorders,
which include: antihyperglycemic, hypolipemiant, antiinflammatory, cardioprotective,
and antioxidant activities. These properties have been attributed to the presence of
bioactive compounds such as phenols, flavonoids, and tannins in different parts of the
plant, albeit the knowledge on their mechanisms of action is scarce. This mini-review
highlights the cardiometabolic properties of S. cumini by correlating its already identified
phytochemicals with their described mechanisms of action. Data herein compiled show
that some compounds target multiple metabolic pathways; thereby, becoming potential
pharmacological tools. Moreover, the lack of clinical trials on S. cumini usage makes it
a fruitful field of interest for both scientific community and pharmaceutical industry.
Keywords: black plum, jamun, myrtaceae, phenolic compounds, metabolic syndrome, ethnopharmacology,
medicinal plants, complementary and alternative medicine
INTRODUCTION
Cardiometabolic syndrome is associated with multiple risk factors including insulin resistance,
dyslipidemia, hypertension, and obesity (Alberti et al., 2009). According to World Health
Organization, every year about 2.8 million people die worldwide due to overweight or obesity
(Lim et al., 2012). Prevalence of diabetes appears with projections to aﬀect about 439 million
adults by 2030, whereas cardiovascular diseases account for 30% of deaths annually, including
both developed and developing countries (Shaw et al., 2010). Because of their chronic degenerative
nature, cardiometabolic-related disorders have long-lasting treatments, costly for both the patient
and the health services, in addition to potentially harmful side eﬀects caused by polytherapeutic
regimens (Yanovski and Yanovski, 2014). In this context, herbal medicines have become the major
source of bioactive molecules and emerged as potential therapeutic tools to fulﬁll a multiple-target
strategy, especially because of their inherented large-scale structural diversity as compared with
synthetic compounds (Prabhakar and Doble, 2008; Vasudeva et al., 2012).
Myrtaceae family comprises about 121 genera with 3800–5800 species of shrubs and trees
distributed mainly in tropical and subtropical areas of the world (Stefanello et al., 2011). The
genus Syzygium, a leading member of this family, embrace 1100 species with deserving attention
to Syzygium cumini (L.) Skeels (syn.: Eugenia jambolana, Syzygium jambolanum), which has been
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used in the treatment of numerous diseases, especially diabetes
(Ayyanar and Subash-Babu, 2012). The use of S. cumini was
introduced in western medicine in the mid-nineteenth century,
when the ﬁrst reports on the investigation of its antidiabetic
properties were published (Helmstadter, 2008). S. cumini is a
large tree native from Indian subcontinent, but widely cultivated
in many countries in Asia, Africa, and South America (Srivastava
and Chandra, 2013). It is popularly known as jamun in India,
black plum in Europe, jambolan in Spanish-spoken countries and
jambolão in Brazil (Corrêa, 1974).
S. cumini is known to possess wide range of medicinal
properties, which have been attributed to the presence of
bioactive compounds in diﬀerent parts of the plant. The leaves are
used in dermopathies, gastropathies, constipation, leucorrhea,
and diabetes; fruits are used in the treatment of pharyngitis
and splenic diseases; whereas barks are used as astringents,
anthelmintic, and carminative. Furthermore, seeds are used
as astringents, diuretic, and especially in the treatment of
diabetes (Warrier, 1997; Helmstadter, 2008; Baliga et al., 2011).
Pharmacological studies have expanded the biological activities
of S. cumini, which include antihyperglycemic, antiinﬂammatory,
antibacterial, cardioprotective, and antioxidant (Kumar et al.,
2008a; Rekha et al., 2008; Sharma et al., 2008b, 2011; Mastan
et al., 2009; Arun et al., 2011; Tanwar et al., 2011). Likewise,
some remarkable and well-conducted literature surveys on
pharmacological properties, phytochemical constituents as well
as nutritive value of S. cumini have been published along the
last decade (Helmstadter, 2008; Ayyanar and Subash-Babu, 2012;
Baliga et al., 2013; Srivastava and Chandra, 2013).
Notwithstanding those ﬁndings, however, there is scarcity of
data on the relationship of its secondary metabolites with the
described biological eﬀects, especially on the mechanisms of
action of these compounds. Therefore, this mini-review is aimed
to speciﬁcally study the cardiometabolic properties of secondary
metabolites already identiﬁed in this plant species, correlating
them with their potential mechanisms of action. For this purpose,
a detailed literature survey has been carried out using both
preclinical and clinical studies as an attempt to identify the
molecular mechanisms of action for the compounds identiﬁed in
the various parts of S. cumini, even considering theymay not have
been necessarily isolated from this plant species, but had the same
chemical identity of those found in it.
PHYTOCHEMICAL CONSTITUENTS
Various secondary metabolites viz., ﬂavonoids, phenolic acids,
tannins, and terpenes have been reported in diﬀerent parts of
S. cumini (Table 1). For instance, leaves of this plant species
contain high levels of ﬂavonoids, especially quercetin, myricetin,
myricitrin, kaempferol, and their glucoside derivatives, in
addition to simple phenols like ellagic acid, ferulic acid,
chlorogenic acid, and gallic acid (Mahmoud et al., 2001; Timbola
et al., 2002; Ruan et al., 2008). The essential oil of leaves is
prevalent in terpenes such as α-pinene, β-pinene, α-limonene,
α-cadinol, pinocarvone, pinocarveol (Shaﬁ et al., 2002; Mohamed
et al., 2013). The seeds are the most studied part of the plant,
being especially high in hexahydroxydiphenic (HDDP) acid-
derivated hydrolyzable tannins, terpenes like as α-terpineol,
eugenol, betulinic acid, and the same abovementioned phenolic
acids (Bhatia and Bajaj, 1975; Ramya et al., 2012). Flowers
have been found to show a very similar chemical composition
to seeds, although pharmacological and chemical studies on
this part are scarce (Baliga et al., 2011; Gordon et al., 2011).
In addition, fruits also contain anthocynins, like as cyanidin,
delphinidin, and petudinine, which give them a bright violet
color (Ramya et al., 2012). Stem bark has essentially the same
phenolic acids, ﬂavonoids, and terpenes described already for
other parts of S. cumini (Bhatia and Bajaj, 1975; Baliga et al.,
2011).
CARDIOMETABOLIC PROPERTIES AND
POTENTIAL MECHANISMS OF ACTION
Antihyperglycemic Activity
Use of S. cumini in the ﬁght against diabetes has been studied by
western medicine since more than 130 years (Helmstadter, 2008).
In recent years, numerous preclinical studies have evaluated
extracts of various parts, especially seeds, of this plant species
for anti-hyperglycemic activity (Ravi et al., 2003; Schossler
et al., 2004; Anandharajan et al., 2006; Sharma et al., 2008a,b;
Ramya et al., 2012; Silva et al., 2012). Blood and urine glucose
levels of streptozotocin-induced diabetic rats were decreased
upon 30-days treatment with ethanolic extract of seed at doses
of 100 mg/kg/day (Ravi et al., 2003). In addition to blood
glucose lowering eﬀect, ﬂavonoid-rich extract of seed was also
shown to recover peripheral glucose tolerance in streptozotocin-
induced diabetic rats (500 mg/kg/day, 21 days) (Sharma et al.,
2008a) and mice (300 mg/kg/day, 15 days) (Sharma et al.,
2008b). Those eﬀects were ascribed to increased activity of
peroxisome proliferator-activated receptors (PPAR) alpha and
gamma, which was assessed in 3T3-L1 preadipocytes incubated
for 24 h with increasing concentrations (1–100 mg/mL) of
ﬂavonoid-rich extract of seed. In this same study, seed extract
was shown to possess insulinotropic activity, which may be
involved in the abovementioned eﬀects (Sharma et al., 2008a).
Considering ﬂavonoids already identiﬁed in S. cumini seed
(Table 1), antihyperglycemic eﬀect of rutin was attributed
to inhibition of glucose metabolism enzymes hexokinase and
glucose-6-phosphatase (Kamalakkannan and Prince, 2006). As
highlighted in Figure 1, rutin (0.5–8 mM) also increased
insulin secretion in streptozotocin-treated pancreatic islets of
rats (Esmaeili et al., 2009). On the other hand, 20 μM
quercetin stimulated insulin secretion by activation of L-type
calcium channels (Figure 1) in isolated rat beta cells (Bardy
et al., 2013). Nevertheless, quercetin has also been described
to increase insulin sensitivity by improving the production of
the adipocyte-derived factors, like adiponectin and leptin (Wein
et al., 2010).
S. cumini has also been described to promote other insulin-
related eﬀects. Incubation of methanolic extract of leaf (1 ng/mL-
10μg/mL) with cultured L6 myotubes for 0.5 and 24 h was found
to increase mRNA expression of glucose transporter (GLUT)-4
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TABLE 1 | Phytochemical compounds identified in different parts of Syzygium cumini.
Plant part Metabolite
class
Identified compounds Reference
Leaf Flavonoids Catechin, kaempferol, myricetin, myricetin 3-O-β-D-glucuronopyranoside, myricetin-4′-methyl ether
3-O-α-rhamnopyranoside, myricetrin 4′ ′-O-acetate, myricetrin 4′ ′-O-acetyl-2-O-gallate, myricitrin,
quercetin -3-O-α-rhamno_ pyranoside
Mahmoud et al., 2001
Phenolic acids Caffeic acid, chlorogenic acid, ellagic acid, ferulic acid, gallic acid Mahmoud et al., 2001;
Timbola et al., 2002;
Ruan et al., 2008
Tannins Nilocetin Mahmoud et al., 2001
Terpenes α-pinene, α-cadinol, pinocarvone, pinocarveol, α-terpeneol, myrtenol, eucarvone, muurolol,
myrtenal, cineole, geranylacetone
Shafi et al., 2002;
Mohamed et al., 2013
Seed Flavonoids Quercetin, rutin, 3,5,7,4-tetrahydroxy flavanone Bhatia and Bajaj, 1975;
Karthic et al., 2008
Phenolic acids Caffeic acid, ellagic acid, ferulic acid, gallic acid Bhatia and Bajaj, 1975
Tannins Corilagin, 3,6-HHDP glucose, 4,6-HHDP glucose, 1-galloyl glucose, 3-galloyl glucose Bhatia and Bajaj, 1975
Terpenes α-terpineol, β-pinene, β-terpinene, betulinic acid, eugenol Williamson et al., 2002;
Karthic et al., 2008
Fruit Flavonoids Myricetin, myricetin deoxyhexoside Gordon et al., 2011
Phenolic acids Ellagic acid, gallic acid Reynertson et al., 2008;
Gordon et al., 2011
Tannins HHDP-galloyl glucose, trigalloylglucose Gordon et al., 2011
Terpenes Citronellol, geraniol, hotrienol, nerol, β-phenylethanol, phenylpropanal Vernin et al., 1991
Anthocyanins Cyanidin, delfinidin, petudinin Veigas et al., 2007
Flower Flavonoids Kaempferol, myricetin, dihydromyricetin, myricetin-3-L-arabinoside, isoquercetin, quercetin,
quercetin-3-D-galactoside
Subramanian and Nair,
1972
Phenolic acids Ellagic acid Baliga et al., 2011
Terpenes Eugenol, oleanolic acid Ramya et al., 2012
Stem bark Flavonoids Myricetin, quercetin, kaempferol Baliga et al., 2011
Phenolic acids 3,3′-di-O-methyl ellagic acid, 3,3′ , 4-tri-O-methyl ellagic acid, gallic acid Bhatia and Bajaj, 1975;
Ramya et al., 2012
Terpenes β-siterol, friedelin, betulinic acid Ramya et al., 2012
HHDP, hexahydroxydiphenic acid.
and phosphatidylinositol 3-kinase (PI3 kinase), both important
mediators of insulin action in adipocytes and skeletal muscle
(Anandharajan et al., 2006). Myricetin (1 mg/kg, 3× per day,
14 days), one of the most prevalent ﬂavonoids in the leaf, has
been shown to improve GLUT-4 expression in both adipose tissue
and skeletal muscle as well (Figure 1; Liu et al., 2007). Flavonoid-
rich extract of S. cumini leaf (300 mg/kg/day, 15 days) reduced by
50% the expression of aldose reductase in renal tissue of diabetic
rats (Sharma et al., 2008b), an eﬀect previously described for
phenolic compounds, such as myricetin, quercetin, kampferol,
and ellagic acid (Haraguchi et al., 1998). The use of S. cumini
(300 mg/kg/day, 15 days) elevated the concentrations of glycogen
in liver and skeletal muscle, suggesting a stimulatory eﬀect on
glycogen synthase or glycogenolysis inhibition (Sharma et al.,
2008b). These eﬀects have been described for oleanolic acid
(5–100 μM) (Ha et al., 2009) and caﬀeic acid (200 g/kg/day,
5 weeks) (Jung et al., 2006), compounds found in ﬂowers and
seeds, respectively. In vitro studies showed that betulinic acid
and 3,5,7,4′-tetrahydroxy ﬂavanone isolated from S. cumini seed
inhibited pancreatic α-amylase, which may cause diminished
intestinal absorption of carbohydrates (Karthic et al., 2008).
Nevertheless, bark extract (1 g/kg/day, 30 days) was shown to
regenerate cells from pancreatic duct (Schossler et al., 2004).
Antihyperlipidemic Activity
Flavonoid-rich extract of S. cumini seed (300 mg/kg/day, 15 days)
was described to reduce total cholesterol, LDL-cholesterol, and
triacylglycerol as well as raise HDL-cholesterol levels (Sharma
et al., 2008b). Similar results were found for aqueous extract
of fruit at doses of 100 and 200 mg/kg (Rekha et al., 2008),
for hydroalcoholic extract of seed kernel (100 mg/kg/day,
30 days) (Ravi et al., 2005) and for administration of Dihar
(100 mg/kg/day, 6 weeks), an Indian mixture of herbs containing
S. cumini (Patel et al., 2009). In all the abovementioned studies,
dyslipidemia secondary to streptozotocin-induced diabetes was
used as animal model to assess S. cumini antihyperlipidemic
activity, which have been mainly ascribed to the inhibition
of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase
(Figure 1), the enzyme responsible for cholesterol synthesis (Ravi
et al., 2005; Sharma et al., 2008b, 2011). Flavonoids found in
S. cumini (Table 1) are expected to account for this activity,
since it has been described that this class of compounds increases
the expression of cAMP-dependent phosphokinase, enzyme
responsible for HMG-CoA reductase inhibition (Havsteen,
2002). However, such eﬀects might also be due reduction of
intestinal absorption of cholesterol, as well as, increased free
fatty acid and triacylglycerol clearances subsequent to insulin
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FIGURE 1 | Biological properties and main mechanisms of action described for the most prevalent polyphenolic compounds identified in Syzygium
cumini. Polyphenolic compounds identified in different parts of S. cumini are shown and connected to target mechanisms and/or organs by arrowheadlines for
activating pathways and interrupted lines for inhibiting pathways. Antihyperglycemic effects of quercetin and rutin have been ascribed to the stimulus of insulin
secretion through blockage of L-type calcium channels on pancreatic beta cells, a mechamism also shared by quercetin and myricetin for vasorelaxant and
antihypertensive properties. Quercetin and phenolic acids, such as ellagic and gallic acids, inhibit 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase in the liver,
concurring for antihyperlipidemic properties. Myricetin also improves glucose homeostasis by stimulation of GLUT-4 expression in both adipose tissue and skeletal
muscle. Notwithstanding the abovementioned effects, all the showed compounds possess well-characterized antioxidant activity, which is also expected to underlie
these cardiometabolic properties of S. cumini.
action improvement. (Ravi et al., 2005; Birari and Bhutani, 2007;
Sharma et al., 2012). In fact, preliminary data from our group has
pointed out that hydroethanolic extract of S. cumini leaf inhibits
both activity and expression of hepatic microsomal triglyceride-
transfer protein, which is further controlled by insulin signaling
pathways. Nevertheless, quercetin has been recently shown to
prevent OP9 mouse stromal cells diﬀerentiation into adipocytes
by downregulation of adipogenic genes (Seo et al., 2015).
Cardioprotective Activity
S. cumini has also been reported to promote hypotensive
and antihypertensive eﬀects. Chronic administration of
hydroalcoholic extract of S. cumini leaf (100 and 250 mg/kg/day,
20 weeks) reduced blood pressure in normotensive rats,
an eﬀect further corroborated by decreased reactivity of
vascular smooth muscle observed upon incubation of its
chloroform (0.25 and 0.5 mg/mL) and aqueous fractions
(0.1, 0.25, and 0.5 mg/mL; Ribeiro, 2007). More recently,
the same group showed a dose-dependent reduction of
blood pressure and heart rate on spontaneously hypertensive
rats submitted to 8-weeks treatment with the same extract
(0.5 g/kg/day) (Ribeiro et al., 2014). In both studies, authors
speculated the extract might contain some compound able
to non-competitively blockade L-type calcium channel.
As depicted in Figure 1, myricetin has been reported to
promote potent vasodilation by impairment of calcium
inﬂux (Herrera et al., 1996), similarly to quercetin, whose
vasospasmolytic eﬀect has been ascribed to blockage of
calcium inﬂux through L-type calcium channels (Hou et al.,
2014).
Besides its eﬀects on vasomotricity, S. cumini seems to
improve hemodynamics as well. In a recent work, platelets
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collected from diabetic patients were incubated with aqueous
extract of S. cumini leaf (100 and 200 μg/mL) resulting in
lower platelet aggregation and decreased oxidative damage,
as assessed by measurement of lipoperoxide and nitric oxide
levels and superoxide dismutase activity. The extract was
still found to increase platelet cell membrane ﬂuidity and
to stimulate Na+/K+-ATPase activity (Raﬀaelli et al., 2014).
In earlier work, De Bona et al. (2010) had already reported
that same concentrations of aqueous extract of S. cumini leaf
decreased adenosine deaminase and 5′-nucleotidase activities,
important thrombogenic enzymes, when incubated with platelets
from diabetic patients. Phenolic compounds identiﬁed in
the extract, such as gallic acid, chlorogenic acid, and rutin,
were suggested as possible candidates for the abovementioned
activities. Moreover, administration of methanolic extract of seed
(200 mg/kg) previously to isoproterenol-induced infaction in
rats, reduced serum levels of myocardial necrosis biomarkers,
speciﬁcally aspartate aminotransferase, alanine aminotransferase,
uric acid, creatine phosphokinase, and lactate dehydrogenase
(Mastan et al., 2009). Notwithstanding, administration of
α-hydroxy cinnamic acid (10, 15, and 20 mg/kg/day, 30 days),
isolated from aqueous extract of S. cumini fruit, to high fat-
fed diabetic rats promoted antiatherosclerotic eﬀects mainly
characterized by decreased oxidized LDL levels, modulation
of endothelial nitric oxide synthase, lower expression of
soluble vascular cell adhesion molecule-1 and signiﬁcant
reduction of atherogenic lipoprotein apolipoprotein B100
along with an increase of apolipoprotein A1 (Tanwar et al.,
2011).
Antiinflammatory Activity
Inﬂammatory processes are directly involved in the development
of cardiometabolic diseases including atherosclerosis, type 2
diabetes, and cancer (Hotamisligil, 2006). Methanolic and ethyl
acetate extracts of S. cumini leaf (200 and 400 mg/kg) reduced
carrageenan-induced paw edema in rats (Jain et al., 2011).
Methanolic extract of seed (250 and 500 mg/kg, 21 days)
also reduced paw edema volume and leukocyte migration in
rats with adjuvant-induced arthritis (Kumar et al., 2008b).
Ethanolic extract of the bark (100, 300, and 1000 mg/kg)
reduced the production of prostaglandin E2, serotonin, and
histamine (Muruganandan et al., 2002). Similarly, pre-treatment
of mice with ethanolic extract of leaf (25, 50, and 100 mg/kg)
reduced systemic production of pro-inﬂammatory factors, such
as interleukin-5 (Brito et al., 2007), whereas TNF-α and
NO· production was decreased at doses of 5 or 50 mg/kg
administered 6-h previous to inﬂammation induction (Maciel
et al., 2008).
Antioxidant Activity
Polyphenolic and related antioxidant compounds are recognized
as important cardiometabolic agents since they scavenge
reactive oxygen/nitrogen species and stimulate antioxidant
defenses (Valko et al., 2007), which may be involved in all
the aforementioned activities of S. cumini (Figure 1). Oral
administration of aqueous extract of seed (500, 1000, and
1500 mg/kg/day, 5 days) to mice treated with urethane 7,12-
dimethyl benzanthracene resulted in reduced chromosomal
damage, signiﬁcantly inhibited hepatic lipid peroxidation,
which was associated with signiﬁcantly increased activity of
glutathione S-transferase, superoxide dismutase, and catalase
(Arun et al., 2011). Pre-treatment of cyclophosphamide-
administered rats with methanolic extract of S. cumini
fruit (100 and 200 mg/kg/day, 14 days) resulted in reduced
formation of hepatic malondialdehyde, lower frequency of
aberrant metaphases, reduced formation of micronuclei,
decreased cytotoxicity against marrow cells and increased
activity of antioxidant enzymes, like as superoxide dismutase
and catalase, besides increased GSH levels (Tripathi et al.,
2013).
Considering in vitro studies, methanolic extract of S. cumini
leaf and branch (1–15 μg/ml) has been shown to strongly
act against OH· and DPPH· radicals, and decreased Fe3+ to
Fe+2 reduction in the FRAP assay. Such activities showed a
strong correlation with the high content of polyphenols and
ﬂavonoids present in the extract (Eshwarappa et al., 2014). In
another report, antioxidant activity of ethyl acetate fraction
(15.6–125 μg/mL) prepared frommethanolic extract of S. cumini
leaf was also correlated with its polyphenolic composition,
especially to ferulic acid and catechins present in the extract
(Ruan et al., 2008). Aqil et al. (2012) reported that ethanolic
extracts of fruit and seed, at diﬀerent concentrations, showed
strong antioxidant activity assessed by mean of distinct assays,
such as ABTS·+, DPPH·, FRAP, and ORAC. These extracts also
showed antiproliferative activity on lung cancer cells, making
them potential sources of anticarcinogenic agents. Anthocyanins
(delphinidin, cyanidin, petunidin, peonidin, and malvidin),
besides ellagic acid and its derivatives (ellagitannins) identiﬁed in
both extracts were suggested to be responsible for the antioxidant
and antiproliferative activities (Aqil et al., 2012). Antioxidant
activity of S. cumini fruit has also been shown to be due to gallic
acid, as well as, derivatives of tetragalloyl glucose and myricetin
(Gordon et al., 2011).
TOXICITY
Several studies have shown that S. cumini do not produce acute or
chronic toxicity when given by oral route. General toxicological
screenings including behavioral, histomorphological as well as
blood hematological and biochemical parameters have been
conducted for extracts from seed (Chaturvedi et al., 2007), fruit
(Kumar et al., 2008a), and leaf (Silva et al., 2012) of S. cumini,
with no toxic eﬀect noticed. Silva et al. (2012) demonstrated that
acute administration of hydroalcoholic extract of leaf at doses as
high as 2 g/kg produced no toxic eﬀects in rodents. The same
study demonstrated that chronic treatment for up to 180 days
at doses of 50, 100, and 250 mg/kg did not cause hematological,
biochemical, or histological alterations in target organs (Silva
et al., 2012). These results are further corroborated by ﬁndings of
potential hepatoprotective eﬀect of ethanolic extract of S. cumini
fruit, without any harmful side eﬀects in animals (Bilal et al.,
2011).
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CLINICAL STUDIES
Notwithstanding all the accumulated knowledge on the
pharmacological properties of S. cumini, very limited data has
come from clinical trials (Helmstadter, 2008). A study conducted
by Srivastava et al. (1983) showed that acute administration
of capsuled seed powder (4–24 g) to patients with severe
diabetes notably reduced blood glucose levels in both fasting
and post-prandial condictions. Similarly, Kohli and Singh (1993)
reinforced the eﬀects of seed powder (12 g/day, 3 months) on
type 2 diabetes mellitus patients by showing that besides a 30%
reduction of serum glucose levels, treatment also improved other
classical symptoms of diabetes, like polyphagia, polyuria, and
polidisia. On the other hand, a single administration of decocted
dried powdered leaves of S. cumini (2 g in 250mLwater) to young
normoglycemic patients had no eﬀect on serum glucose levels
(Teixeira et al., 2000). In a second approach, Teixeira et al. (2006)
administered the same decoction to type 2 diabetic patients for
28 days observing no eﬀect on glucose levels. Albeit contradictory
results showed above, the plethora of preclinical studies on the
cardiometabolic properties of S. cumini supports the necessity
of well-designed trials that allow an eﬃcient assessment of its
therapeutic potentials in humans. In addition, standardization
of extraction method and characterization of phytochemicals
present in the extracts are fundamental to the success of such
trials.
CONCLUSION
The present work enlightens cardiometabolic properties
described for S. cumini, which have been attributed to a
limited amount of phytochemicals, particularly ﬂavonoids,
phenolic acids, and tannins (Table 1). As summarized in
Figure 1, some compounds like myricetin, quercetin, rutin,
ellagic, and gallic acids seem to be able to act on distinct
pathways of cardiometabolic disorders, thus emerging as
potential multi-targeted drugs. Nevertheless, the knowledge
on their precise mechanisms of action is scanty and still
deserves in-depth scientiﬁc research, especially concerning their
jointed action as a phytocomplex. Finally, though toxicological
studies have shown the species safety, clinical trials are barely
inexistent pointing out a golden Eldorado for pharmaceutical
companies.
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